cyrilzakka/clinical-trials huggingface dataset:
Evaluation of a Resiliency Program for Fathers of Children and Youth With Special Health Care Needs

Based on findings from our prior trials with parents of children with learning and attentional disabilities and parents of children with autism spectrum disorder (Kuhlthau et al., 2020; Park et al., 2020; IRB approved: #:2016P001622 and 2016P002037 respectively), the investigators propose to pilot test and refine the adapted resiliency intervention (SMART-3RP) among fathers of children with special health care needs.

This is an open pilot study. Based on Phase I findings (IRB #2021P002838), the investigators propose to enroll up to 12 fathers (in 2 groups) of children and youth with special health care needs (CYSHCN) in the adapted SMART-3RP intervention. The SMART-3RP is an 8-session mind-body resiliency intervention that will be conducted virtually. Participants will complete the study survey at baseline and immediately following the intervention. As this is a pilot, participants will also be asked to provide weekly feedback on program sessions and participate in an exit interview following the intervention. The intervention may be iteratively modified as the investigators receive feedback from participants.

Eligibility Criteria:
Inclusion Criteria:

* Self-reported identify as father or male guardian of at least one child with special health care needs (e.g., autism spectrum disorder, cerebral palsy, dyslexia)
* Age 18 or older
* Ability to participate in group, virtual sessions including access to computer, tablet, or smartphone and internet.

Exclusion Criteria:

* unable to speak or read English
* unwilling or unable to participate in the study
* considered medically or otherwise unable to participate by the study PI.
Ureteroscopy With High-powered Holmium:Yag Laser Lithotripsy With and Moses On or Moses Off

The purpose of this study is to compare Moses 2.0 pulse modulation technology and the standard high powered Holmium Laser lithotripsy and how it will affect time in the operating room, time using the laser, laser energy, and stone free rates.

Currently Moses 2.0 laser technology is FDA approved and currently used in practice since 2021. No study to this date has compared Moses 2.0 without pulse modulation laser technology to Moses 2.0 with pulse modulation laser technology.

The study will be including kidney and ureteral stones (a kidney stone located in the tube between the kidney and the bladder) that are 6mm and greater, but less than 20 mm in size undergoing ureteroscopic treatment. High powered lasers are used for "dusting". Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.

On the day of surgery, the treatment assigned to the patient will be determined by chance, like flipping a coin. Neither the patient nor the study doctor will choose the treatment type. Each patient will have an equal chance of being given either surgical treatment. One group will have stones treated with high powered laser dusting with Moses 2.0 pulse modulation and the dust produced will pass spontaneously through the urine. The other group will have stones treated with standard of care high power laser fragmentation and the dust produced will pass spontaneously through the urine. The surgical procedure will not differ from the treatment a patient would receive if he/she were not in this study.

8 to 12 weeks after surgery, participants will undergo a standard of care renal bladder ultrasound (RBUS) and Kidney Ureter Bladder Abdominal X-ray (KUB) to evaluate for stones and hydronephrosis, which is swelling of the kidney due to build-up of urine.

If there are abnormal findings on the RBUS or KUM at the 8 to 12 week follow-up, participants will be asked to return to the urology clinic and may have to repeat imaging to ensure participants did not develop a postoperative condition.

Eligibility Criteria:
Inclusion Criteria:

* Undergoing ureteroscopy and laser lithotripsy
* Stone size ≥8 but \< 20 mm in the proximal ureter or kidney. Multiple stones ≤4 are allowed. Bilateral surgeries are allowed
* Willing to sign informed consent

Exclusion Criteria:

* Staged surgery
* Nephrocalcinosis
* Participant is less than 18 years of age
* Inability to provide informed consent
* Members of vulnerable patient populations
Ballet Training in Children With Idiopathic Coxa Antetorta

This study looks at how ballet training affects movement and personal feelings in children with a condition called idiopathic coxa antetorta.

Increased femoral anteversion (IFA) occurs when the top of the thigh bone tilts forward more than normal. Many healthy kids and teens aren't considered to have a problem with this as long as they show no symptoms, since it often corrects itself by the time they reach ages 12 to 14. However, experts believe this condition might lead to complications later in life. Research indicates that children with IFA may be more prone to issues like kneecap misalignment, knee pain, and even arthritis as they grow older. This is likely due to the way their knees bend differently when they walk. Kids with IFA often walk with their toes pointing inward, which increases their chances of tripping and falling. They may also experience pain that interferes with their daily activities. It is assumed that strengthening the hips and improving hip flexibility could help reduce the need for compensatory movements, ultimately lowering the risk of tripping, falling, and experiencing pain in everyday life. This study is a randomized controlled trial aimed at examining how ballet training influences knee movement-specifically knee flexion-during walking in children with idiopathic coxa antetorta. The goal is to determine whether ballet training enhances the children's overall mobility and how they feel about their ability to move. Additionally, the study seeks to find out how this training can be effectively incorporated into the daily routines of affected schoolchildren.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of idiopathic coxa antetorta with FNA\> 30°
* Children between 8 and 12 years of age
* Cognitive abilities must include: Ability to actively participate in a 60-minute ballet class; Ability to communicate pain or discomfort; Ability to attend training, testing and follow-up sessions. All included participants can make decisions on their own and do not show any signs of mental or cognitive limitations.

Exclusion Criteria:

* Any surgery within 6 months prior to the start of the study or surgery scheduled during the study period. Other medications can be continued as prescribed by the participants' physician
* Known cardiovascular or pulmonary diseases that have not received medical clearance to participate in the physical exercise intervention
* Neurological or other musculoskeletal comorbidities
* The children should not have completed any ballet training in the last 12 months
* Pregnancy
Multicenter Registry for Patients With Childhood.Onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts

KRANIOPHARYNGEOM Registry 2019 will prospectively collect and descriptively analyse data on diagnostics, treatment, and follow-up of patients with craniopharyngioma. In continuation of preceding studies also patients with xanthogranuloma, meningioma, pituitary adenoma, prolactinoma and cystic intracranial malformations will be registered.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosed with craniopharyngioma for the first time
2. Age at diagnosis 18 years or less of age
3. Agreement from patient's parents or legal guardian as well as the patient

Exclusion Criteria:

1. Age at diagnosis over 18 years of age
2. Diagnosis different from craniopharyngioma
RHEUPP - A Rheumatological Follow-up Management App

The purpose of this Non-inferiority Randomized Clinical Trial is to evaluate the effectiveness of RHEUPP App during telehealth follow-up in a population of Rheumatoid Arthritis patients from a Tertiary Rheumatology Service in South Brazil.

The main question\[s\] it aims to answer are:

• Using RHEUPP App in telemedicine is not inferior to usual care in terms of means obtained by CDAI.

Participants will be stratified by CDAI and then randomized 1:1 for intervention or control group. They will be evaluated at study starting, in 3 and 6 months, an extended evaluation after 12 months of recruitment is predicted.

Researchers will compare intervention and control group to detect differences between usual care and Telehealth follow-up and determine if the last is not less effective in our study population of rheumatic patients.

Participants with access to digital media will be sent a weblink for accessing the study's electronic questionnaires by electronic message or email, with a maximum interval of one week before or after your in-person consultation, according to the research participant's preference. A tablet will be made available to patients who choose to carry out the survey on the day of their in-person assessment. Participants randomized to the intervention group will receive guidance regarding the download or access to the RHEUPP application, with a period of training and adaptation to the tool, to be carried out by Social Monitor.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (18y or older)
* Rheumatoid Arthritis according to the 2010 EULAR/ACR criteria
* Access to digital media (electronic messages, e-mail)

Exclusion Criteria:

* Other rheumatological diseases (except Sjögren's Syndrome)
* Inability to understand the instrument in general or assistance from third parties (family member or caregiver) in carrying out the questionnaire at a disadvantage
* Incomplete information in data collection
* Patients with changes in their treatment in the last 4 weeks or treatment change plan at recruitment to the study.
POCD: Correlations With the Gene Polymorphism and the Concentrations of Plasma Homocysteine, Folic Acid and Vitamin B12.

To study on the Postoperative Cognitive Dysfunction: Correlations With the Gene Polymorphism and the Concentrations of Plasma Homocysteine, Folic Acid and Vitamin B12. To explore whether the gene polymorphism and the concentrations of plasma homocysteine, folic acid and vitamin B12 could be used as predictor(s) of POCD and to provide reference for POCD prevention, early detection and timely diagnosis and treatment.


Eligibility Criteria:
Inclusion Criteria:

* Non-cardiac surgery patients;
* Age is greater than or equal to 60 years old;
* Han Nationality, mother tongue is chinese;
* The MMSE score: Illiteracy is greater than or equal to 17 points, primary school is greater than or equal to 20 points, higher secondary school is more than 24 points;
* The Geriatric Depression Scale (GDS) grade 1 or 2;
* The important function without serious heart, brain, liver, kidney, lung and other organs;
* The ASA class I or II;
* The people signed informed consent.

Exclusion Criteria:

* The diagnosis of neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's syndrome, multiple sclerosis, schizophrenia, depression, etc.;
* Had severe head and face disease, trauma history or history of surgery;
* The serious body disease and tobacco, wine and other substance abuse history;
* The presence of malignant tumor with shorter survival disease.
Serum VEGF as a Tubal Pregnancy Marker

The aim of the present study was (i) to evaluate whether a single measurement of VEGF would allow us to distinguish between intrauterine pregnancy (normal and abnormal) and EP and (ii) to correlate the levels of VEGF with serum levels of progesterone and β-hCG in each subgroup.

Ninety patients were selected from a population of women presenting to the Hospital das Clínicas of the University of São Paulo Medical School from October 2006 until September 2007 and were divided in three subgroups: (i) abnormal (arrested) intrauterine pregnancy (defined as a gestational sac greater than 16 mm of mean diameter without fetal tissue or a embryo greater than 5 mm without embryo cardiac activity); (ii) tubal pregnancy (no evidence of intrauterine pregnancy, presence of a adnexal mass, suboptimal rise of serum hCG levels in 48 hours); all tubal pregnancies were surgically treated and were histologically confirmed, they did not receive any methotrexate treatment before operation; (iii) normal intrauterine pregnancy (intrauterine gestational sac, embryo vitality confirmed).

Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.


Eligibility Criteria:
Inclusion Criteria were:

* women that had a positive hCG test and presented with either abdominal pain or vaginal bleeding; all pregnancies were singletons, spontaneously conceived, with accurate assessments of their gestational age (42 - 56 days from the first day of the last menstrual period). A detailed informed consent was obtained from each patient before the inclusion.

Exclusion Criteria was:

* non-ampullar tubal pregnancy (surgically confirmed).
Impact of Music Added to the Usual Treatment on the Anxiety of Patients Undergoing Outpatient Cataract Surgery with Topical Anesthesia

Most patients treated for cataract surgery benefit from a short outpatient course with topical local anesthesia.

Having to undergo surgery, especially on the eye, without being asleep, can be stressful. Sometimes waiting in a waiting room with other patients can increase this stress. Patient anxiety may increase blood pressure potentially leading to the prescription of nicardipine to allow surgery to be performed. The patient's anxiety also increases the surgeon's stress, which can alter the conditions for performing the intervention and increase the risk of intraoperative complications.

Besides the administration of anxiolytics, nurses have few options for patients with anxiety. However, the treatment response time is not always appropriate and the patient's cooperation during the procedure can sometimes be impaired.

The effect of music on preoperative anxiety has been evaluated in several studies and has shown a significant decrease in anxiety before surgery.

MusicCare® is a "digital treatment" based on the principles of hypnoanalgesia which has been tested in the management of patients with various pathologies (depression, Alzheimer's disease, chronic pain, etc.) and has shown relative effectiveness. the absence of intervention on the pain and anxiety of patients.

In the context of cataract surgery with topical local anesthesia, we would like to assess the contribution of offering the MusicCare® listening device on patients' anxiety about absence


Eligibility Criteria:
Inclusion Criteria:

* First cataract surgery (first eye)
* Patient scheduled for short outpatient cataract surgery with topical anesthesia

Exclusion Criteria:

* Pregnant or breastfeeding woman.
Open Facet Joint Denervation in the Treatment of Low Back Pain

A single blinded RCT for adult patients with spine pain. One group had a lumbar laminectomy with denervation of the facet joint at the level decompressed. The other group had a lumbar laminectomy without facet joint denervation. Both groups had their back pain and functional limitations measured using a 10 cm visual analogue scale and the Oswestry disability index (ODI). All measures were taken before surgery and at patients' 6, 12 and 24 week follow-up clinic visit.


Eligibility Criteria:
Inclusion Criteria:

* aged 19 or older
* a diagnosis of spinal stenosis
* having neurogenic claudication
* complained of back pain for at least 3 months

Exclusion Criteria:

* previous surgery on their spine,
* fracture, systemic inflammatory disease,
* malignancies or an infection affecting their spine
The Results of Ahmed Valve Operations

Glaucoma drainage devices are usually placed in the superior quadrants. The superotemporal quadrant is usually the site of choice. However, when the upper fornix is scarred and especially when conjunctiva is two fibrotic to enable adequate coverage of tube with a scleral or other patch graft, some surgeons place the tube in one of inferior quadrants.

Glaucoma drainage devices are usually placed in the superior quadrants. The superotemporal quadrant is usually the site of choice. However, when the upper fornix is scarred and especially when conjunctiva is two fibrotic to enable adequate coverage of tube with a scleral or other patch graft, some surgeons place the tube in one of inferior quadrants.

In the present study we will compare the outcome and complicatons of both the superior and the inferior approach for inserting Ahmed Valve implants.

Eligibility Criteria:
Inclusion criteria:

1. Patients at the ages of 20-85 on the date of the surgery
2. The indication for the surgery was: uncontrolled glaucoma with maximally tolerated medical therapy who did not or were not expected to respond to other surgical procedures than seton surgery.
3. Visual acuity of, at least, 20/800 before the operation.
4. Regular post operative follow ups, for at least 1 year.
5. Patients after corneal transplantation for whom the indication of valve implantation was uncontrolled glaucoma.

Exclusion Criteria:

1. A previous seton surgery in the operated eye
2. Uveitic glaucoma patients or history of uveitis in the operated or in the fellow eye.
3. Any inflammatory or ocular surface disease that could affect the healing of the conjunctiva after the surgery ( e.g: OCP)
4. Strabismus or complains of diplopia prior to the seton surgery.
5. Past history of retinal detachment surgery with scleral buckle in the operated eye
6. Past history of endophthalmitis in the operated eye.
A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis

This current study is planned as a dedicated pharmacodynamic (effect of drug on the body) study to investigate the dose response in rhinitic subjects at doses where GSK256066 has been proven to work (200mcg) or expected to (50mcg) work. This study also aims to investigate the lower end of the predicted therapeutic range.


Eligibility Criteria:
Inclusion Criteria:

* The subject is healthy.
* Body mass index less than 29.0 kg/m² , weight range of 55.0kg (females 50kg) to 95.0kg inclusive.
* They have a history of hayfever (repeated yearly episodes).
* They have a positive skin prick test for grass pollen at or within the 12 months preceding the screening visit.
* They have a positive radioallergosorbent test for grass pollen at or within the 12 months preceding the screening visit.
* non-smokers.
* They must have a baseline FEV1\>80% predicted and a baseline FEV1(maximum recorded value)/ forced vital capacity (FVC) (maximum recorded value)\>70%
* They are capable of giving informed consent
* They are available to complete all study measurements.

Exclusion Criteria:

* Pregnant or nursing females.
* Women of childbearing potential who are unwilling or unable to use an appropriate method of contraception.
* The subject has structural nasal abnormalities or nasal polyposis.
* Any respiratory disease other than mild stable asthma that is controlled with occasional use of as-needed short-acting beta-agonists and associated with normal lung function.
* The subject has a history of drug or other allergy that may contraindicate participation.
* The subject has participated in a study with a new molecular entity during the previous 4 months or in any clinical study in the previous 3 months
* The subject is concurrently participating in another clinical study and is exposed to an investigational or a non-investigational drug or device.
* The subject has a screening QTc value \>450msec, PR interval outside the range 120 to 240msec or an ECG that is not suitable for QT measurements.In addition subjects will be excluded if they have a history of atrial and ventricular arrhythmia.
* The subject has a supine blood pressure that is persistently higher than 140/90 millimetres of mercury (mmHg) at screening.
* The subject has donated a unit of blood (450mL) within the previous 3 months or intends to donate within 3 months of completing the study.
* The subject is currently taking regular (or a course of) medication whether prescribed or not, including steroids, vitamins, and herbal remedies (e.g. St. John's Wort). Paracetamol (\<2g/day) and occasional as needed use of short-acting beta agonists is permitted.
* Past or present disease which may affect study. outcome
* The subject regularly, or on average, drinks more than 4 units of alcohol per day - where 1 unit = ½ pint of beer (284mL), or 1 glass of wine (125mL), or 1 measure of spirit (25mL).
* The subject is at risk of non-compliance with the study procedures/restrictions.
* The subject has Hepatitis B, Hepatitis C, or HIV virus.
Premedication Efficacy of Oral Ketorolac and Ketorolac/ Acetaminophen on Post Treatment Pain

The aim of this study is premedication efficacy of analgesics on post endodontic pain. Sixty-six healthy adult volunteers including criteria, are participating. The patients will be divided into 3 groups and will be randomly given one of pre medications including 1) 10 mg Ketorolac, 2) 10 mg Ketorolac plus 1000mg Acetaminophen, and 3)Placebo, 45 minutes before applying the injection. All patients will receive standard root canal treatment. Patients will record their post treatment pain using a Heft parker Visual Analog Scale(VAS). Success will be considered as no or mild pain (VAS≤54)with no need to take analgesic. Data will be analysed using Mann-U-Whitney and Kruskal-wallis tests.

The aim of this study is premedication efficacy of analgesics on post endodontic pain. Sixty-six healthy adult volunteers with age ranged 18-65, non smoking or any medicine consumption, non pregnant or break feeding who haven't received any analgesic during 24 hours before the treatment, are participating. The patients will be divided into 3 groups and will be randomly given one of premedications including 1) 10 mg Ketorolac, 2) 10 mg Ketorolac plus 1000mg Acetaminophen, and 3)Placebo, 45 minutes before the treatment. All patients will receive a standard root canal treatment. Patients will record their post treatment pain using a Heft parker Visual Analog Scale(VAS). Success will be considered as no or mild pain (VAS≤54) with no need to take analgesic during 6, 12, 24 and 48 hours intervals following the treatment. Data will be analysed using Mann-U-Whitney and Kruskal-wallis tests.

Eligibility Criteria:
Inclusion Criteria:

* Patients with age ranged 18-65
* without systemic diseases
* without any medicine consumption
* non smoking
* non pregnant
* non breast feeding
* with asymptomatic irreversible pulpitis ( Visual Analog Scale ≤ 54) in one mandibular molar that needs root canal treatment
* without any medicine consumption or analgesic and sedation who understand and sign the VAS and consent forms.

Exclusion Criteria:

-